Baxter's Upcoming Q2 Earnings: Analyst Says Consistent Performance, Catalysts Can Accelerate Growth & Margins
Portfolio Pulse from Vandana Singh
Baxter International Inc (BAX) is set to release its Q2 2023 financial results on July 27. Stifel analyst recommends buying BAX shares, revising the target price to $56 from $54. Despite being one of the worst-performing large-cap MedTech stocks this year, the analyst believes that positive developments in regulatory approvals, new product launches, and financial leadership can potentially have a favorable impact on the stock. Baxter's fundamentals are expected to improve in the second half of 2023 and throughout 2024.
July 12, 2023 | 5:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Stifel analyst recommends buying BAX shares, revising the target price to $56 from $54. Despite being one of the worst-performing large-cap MedTech stocks this year, the analyst believes that positive developments can potentially have a favorable impact on the stock. Baxter's fundamentals are expected to improve in the second half of 2023 and throughout 2024.
The Stifel analyst's recommendation to buy BAX shares and the upward revision of the target price indicates a positive outlook for the stock. Despite the stock's underperformance this year, the analyst believes that Baxter's fundamentals will improve in the second half of 2023 and throughout 2024 due to positive developments in regulatory approvals, new product launches, and financial leadership.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100